Vamsidhar Velcheti

Vamsidhar Velcheti has been a leading clinical investigator in immunotherapy combinations for non-small cell lung cancer, examining the additive and synergistic effects of checkpoint blockade combined with chemotherapy, antiangiogenic agents, and targeted therapies. His research has contributed to understanding which NSCLC patients derive greatest benefit from IO plus chemotherapy combinations versus PD-1/PD-L1 monotherapy based on PD-L1 expression, tumor mutational burden, and molecular subtype. He has investigated the challenge of combining immunotherapy with EGFR- and ALK-targeted therapies in oncogene-addicted NSCLC, where sequential rather than concurrent combination is typically required due to toxicity. His translational work examining immune landscape characteristics of NSCLC subtypes has contributed to biomarker development for IO combination strategies across lung cancer molecular subtypes.